Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIERRA: durvalumab plus tremelimumab first-line for advanced hepatocellular carcinoma
jRCT2051230057Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoints: Incidence of grade 3 or 4 possibly related to treatment adverse events and Objective response rate. Started Jul 2023; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2051230057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230057.